In vitro studies provide mechanisms by which elevated lipoprotein(a) [Lp(a)] concentrations may promote both thrombosis and atherogenesis. Casecontrol studies have reported raised Lp(a) concentrations in patients with stroke, but prospective studies have failed to confirm the association. A potential confounding factor is that Lp(a) may rise acutely after stroke. We determined Lp(a) concentrations in 164 patients studied at least 21 days after stroke or transient ischaemic attack, and in 91 controls. In the patient group we correlated Lp(a) concentrations with both the degree of carotid stenosis estimated on duplex ultrasonography, and with stroke subtype (large vessel disease, lacunar infarction, and cardioembolic and unknown pathogenesis). There was no difference between Lp(a) concentration in cases and controls [median (quartiles) 0·10 (0'04, 0,39) versus 0·12 (0·04, 0·30) giL, P=0·34]. There was no difference in the proportion of cases compared with controls with a markedly elevated Lp(a) of >0·4 giL (21,3 versus 16,5%, P=0·34). There was non-significant trend towards higher median Lp(a) concentrations in women [median (quartiles) 0·16 (0'04, 0,32) giL versus 0·12 (0'04, 0'28)g/L, P=0·3]. In view of this trend we analysed the differences between cases and controls for each sex separately. Lp(a) concentrations in men were median (quartiles) 0·08 (0'04, 0'26)g/L in the 101 cases and 0·12 (0'04, 0,28) giL in the 43 controls (P= 0·6). Lp(a) concentrations in women were median (quartiles) 0·25 (0'04, 0-44) giL in the 63 cases, and 0·16 (0'04, 0,32) g/L in the 48 controls (P=0·16). Within the patient group there was no difference between Lp(a) concentrations in the different stroke subgroups. There was no relationship between Lp(a) concentrations and mean percentage carotid stenosis (r s = 0·14, P = 0'07). Our results suggest that in an un selected population of men studied more than 3 weeks post event there is no relationship between lipoprotein(a) concentrations and either stroke/transient ischaemic attack, or carotid atheroma. The relationship in women requires further study.
Lipoprotein(a) [Lp(a)] consists of an LDL particle covalently linked by disulphide-bridge formation with a large glycoprotein called apo(a). Apo(a) has a high degree of sequence homology to plasminogen, from which the enzyme plasmin is released by tissue plasminogen activator during fibrinolysis. In vitro experiments suggest that apo(a) interferes with uptake Correspondence: Dr Hugh Markus, Department of Neurology, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK. 360 and activation of plasminogen by receptors on cell surfaces and fibrin. I By inhibiting plasminogen binding elevated Lp(a) concentrations could promote thrombosis and therefore increase myocardial infarction and stroke risk. Some in vitro results support this hypothesis, although in vivo studies are less conclusive.' It has also been suggested that Lp(a) may also promote atherogenesisj? Lp(a) is found in atherosclerotic coronary arteries where it may be preferentially deposited instead of low-density lipoprotein.' Lp(a) binds avidly to matrix components typically found in atherosclerotic plaques, such as fibrin, glycosaminoglycans and fibrinonectin through its apo(a) por~on. 4, 5 Once in the arterial wall Lp(a) may undergo oxidative modification, leading to macrophage uptake and foam cell forrnation.? It may increase LDL delivery and binding in the plaque via an LDL-receptorindependent mechanism," and promote smooth muscle proliferation via reduced plasmin activation of latent growth factor-beta, an inhibitor of smooth muscle growth." A number of cross-sectional studies have reported elevated Lp(a) levels in patients with stroke. 8 -15 In contrast some recent prospective studies have failed to show an association.ts-!? A potential confounding factor is that the elevation of Lp(a) may partially represent an acute phase response.P One method of reducing this confounding effect is to study patients outside the acute phase. We therefore performed a casecontrol study to determine the relationship between Lp(a) levels, measured during the convalescent phase, and arterial cerebrovascular disease. In addition, within the cases we determined the relationship between Lp(a) and the degree of carotid atheroma as determined by high resolution duplex ultrasonography.
PATIENTS AND METHODS
One hundred and sixty-four patients with symptomatic ischaemic cerebrovascular disease (CVD) presenting to a neurology stroke/ transient ischaemic attack (TIA) service were enrolled. Only patients between 21 days and 2 years after the last stroke or TIA were enrolled. Patients with cerebral haemorrhage or venous thrombosis were not studied. In view of the marked ethnic variation in Lpta)!' only Caucasians were studied. Patients' details are shown in Table 1 . Median (range) time from last stroke These two categories were included together as not all patients had echo cardiography (n =62) 4 Tandem pathology (n = 16). More than one cause of stroke, e.g, atrial fibrillation and carotid stenosis or atrial fibrillation and lacunar infarction.
Spouses of the cases were recruited as controls where available; potential controls with stroke (2 cases) were excluded but subjects with risk factors for vascular disease were included; 91 controls were available for study. Blood pressure and serum cholesterol concentration were measured in all controls. In both the patient and the control groups hypertension was defined as CVD either a systolic blood pressure> 160 mmHg, or a diastolic pressure> 95 mmHg, or current treatment with antihypertensive drugs. Raised cholesterol was defined as a cholesterol concentration > 6·5 mmol/L or current cholesterol lowering treatment. After collection, plasma was stored at -60 DC and Lp(a) was measured using an ELISA method (lmmuno Ltd, Sevenoaks, UK). The inter-assay precision of the Lp(a) method was assessed at two levels, 0·20 giL (n = 23) and 0·31 giL (n = 22). Coefficients of variation were 3·7% and 4-4%, respectively. Due to the skewed distribution of Lp(a) concentrations in our data as previously reported/ which persisted despite logarithmic transformation, comparisons between cases and controls and within specific groups were made using the non-parametric Mann-Whitney U statistic and Spearman's correlation coefficient where appropriate, as indicated in the text.
RESULTS
There was no difference between Lp(a) concentration in cases and controls [median (quartiles) 0·10 (0'04, 0'39) versus 0·12 (0'04, 0,30) giL, Mann-Whitney U Test P=0·34]. There was no difference in the proportion of cases compared with controls with a markedly elevated Lp(a) of >0·4g/L (21'3 versus 16'5%, -; test, P=0·34). In contrast hypertension, diabetes, smoking history and male sex were more common among the cerebrovascular patients (Table 1) .
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Within the patient group there was no difference between Lp(a) concentrations in the different stroke subgroups ( Table 2 ). There was no relationship between Lp(a) concentrations and mean percentage carotid stenosis (r, = 0'14, P = 0,07). There was possibly a trend towards an increased percentage stenosis in patients with a Lp(a) concentration> 0-4 giL (Table 3) but this was not significant (ANOVA P=0·18). There was no difference between Lp(a) levels in the 129 patients with stroke compared with the 35 patients with TIA without CT infarct [median (quartiles) 0·08 (0'04, 0'36) versus 0·15 (0'05, 0-47) giL, Mann-Whitney U test, P=0·16].
Within the control group there was no association between Lp(a) concentration and age (r,= -0'08, P=0'4), raised cholesterol (Mann-Whitney Z= -0'5, P=0'6), diabetes (Z= -0'37, P=0'7), hypertension (Z= -0'13, P = 0,9), or smoking history (Z = -0,62, P = o· 5). There was an apparent trend towards higher median Lp(a) concentrations in women [median (quartiles) 0·16 (0'04, 0'32) giL versus men 0·12 (0'04, 0,28) g/L] but this was not significant (Mann-Whitney Z=0'94, P=0·3). In view of this trend we analysed the differences between cases and controls for each sex separately. Lp(a) concentrations in men were median (quartiles) 0·08 (0'04, 0'26) giL in the 101 cases and 0·12 (0'04, O' 28) g/L in the 43 controls (Mann-Whitney U Z= -0'5, P=0·6). Lp(a) concentrations in women were median (quartiles) 0·25 (0'04, 0-44) giL in the 63 cases, and 0·16 (0'04, 0,32) giL in the 48 controls (Mann-Whitney U Z= -1'40, P=0·16).
DISCUSSION
A number of case--eontrol studies have reported an increased Lp(a) concentrations in survivors of stroke,815 and it has been suggested that Lp(a) may be an independent risk factor for stroke. In contrast, case--eontrol studies performed on prospectively acquired data from the Physicians Health Study!" and a Finnish population study'? have failed to confirm this association. A similar picture has emerged in coronary heart disease with most cross-sectional studies-and two prospective studies 20 • 21 reporting an association, but further prospective studies failing to confirm the association.Pv" The reasons for these conflicting results remain uncertain. The prospective studies provide strong data but despite large numbers of subjects there were relatively few strokes in each study, haemorrhagic strokes were not always differentiated from ischaemic strokes, all patients with stroke were not evaluated by the same clinician and protocol of investigations, and the Lp(a) analysis was performed on serum which had been stored for a number of years. The case--eontrol studies benefit from more detailed evaluation of stroke patients although many of the studies were small with control groups of less than 50 subjects, the selection of control groups was not always described, and publication bias may have resulted in publication of positive results. A further major confounding variable is that the raised Lp(a) concentrations in patients with stroke may represent an acute phase response. Lp(a) has been reported to rise transiently after myocardial infarction and following surgery.P-" Most of the case--eontrol studies have studied patients soon after stroke. For this reason we studied patients in the subacute or chronic phase after stroke and TIA. The lack of association we found is consistent with the results from prospective studies. We studied an un selected group of patients with a mean age of66 years and therefore we cannot exclude a role for Lp(a) as an independent risk factor in young patients with stroke as reported in a case--eontrol study in patients in the chronic phase of stroke. 12 However, our data is supported by a recent study in which elevated Lp(a) concentrations were found in acute stroke but were not associated with subsequent recurrent stroke risk. 26 It is possible that Lp(a) could be associated with one particular stroke subtype and that any association may be diluted by including patients with other stroke subtypes. However, we found no difference in Lp(a) concentrations between patients with large vessel disease, lacunar stroke and those with cardiac/uncertain causes. It has been suggested that high Lp(a) concentrations may promote atherogenesis. We found no association between the degree of carotid stenosis and Lp(a) concentrations in the patients with cerebrovascular disease, although there was a trend towards more carotid atheroma in patients with very elevated Lp(a) concentrations (> 0-4 g/L) but this was not significant. In contrast to our results, a strong independent association has recently been reported between carotid stenosis and Lp(a) concentrations in a group of 60 patients studied angiographically.F The mean age of patients in this study (62'5 years) was only slightly younger than in our study. Ultrasound is a better method of detecting lesser degrees of stenosis and another recent study using ultrasound also reported no association between Lp(a) concentrations and carotid atherosclerosis.P However, we cannot exclude the possibility that very elevated Lp(a) concentrations are a risk factor for atheroma in a small subgroup of patients and this association needs further study; nevertheless this does not account for any significant association in an unselected group of patients with stroke and TIA. It is possible that an association may exist in particular high risk populations such as patients with hyperlipidaemia, or premature atherosclerosis in a young age group but this would require further examination in these populations.?
We found apparently higher Lp(a) concentrations in women and a trend towards a difference in Lp(a) concentrations between female cases and controls, in contrast to no difference between male cases and controls. The numbers are relatively small and further studies are required to determine whether this difference is significant. Most population studies have found no difference between Lp(a) concentrations and distributions in men and women 29 ,30 although others have found higher concentrations in women." Most of the individuals studied have been young or middle-aged. In contrast our population was older and most patients were post-menopausal. A rise in Lp(a) has been reported following the menopauset'v? or after bilateral, but not unilateral, oophorectomy," and this rise is reversed following hormone replacement therapy.33,34 One of the two prospective studies of Lp(a) and stroke risk only studied men," while in the other in women, but not men, the median Lp(a) concentrations were 24% higher in cases with either myocardial infarction or stroke than in controls, but this difference was not significant.!?
It is well known that there are differences in Lp(a) results between available methods. This is partly related to different approaches to standardization (whole Lp(a) molecule versus the protein moiety). A recent study compared the most commonly used methods in the British Isles'" and demonstrated that the Immuno ELISA method, which we used, gave results comparable to other methods. Differences in Lp(a) results due to the analytical methodology should however be considered when comparing results between studies.
CONCLUSION
The clinical implication of our study is that Lp(a) is not a useful indicator of stroke risk in routine patients with, or at risk of, stroke. It may be a risk factor in specific populations and further similar studies in non-acute patients are required, particularly in younger patients with very elevated Lp(a) concentrations, and in women.
